Table 2.
Biomarker Category | Biomarker | Definition | Correlation to ICB Response | Data Type | Tumor Type | Reference |
---|---|---|---|---|---|---|
Immune-checkpoint molecule | PD-1 | PD-1 mRNA expression | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [35,36] |
Immune-checkpoint molecule | PD-L1 | PD-L1 mRNA expression | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [8,37] |
Immune-checkpoint molecule | PD-L2 | PD-L2 mRNA expression | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [36,38] |
Immune-checkpoint molecule | CTLA-4 | CTLA-4 mRNA expression | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [8] |
Immune-checkpoint molecule | IMPRES (immuno-predictive score) | A predictor of ICB response in melanoma which encompasses 15 pairwise transcriptomics relations between immune checkpoint genes. | Positive | RNA-seq/NanoString nCounter/MicroArray | Melanoma | [13] |
Tumor-infiltrating lymphocyte (TIL) | CIBERSORT.CD8 | Fraction of tumor- infiltrating CD8 + T cells |
Positive | RNA-seq/MicroArray | Multiple Cancer Types | [17] |
Tumor-infiltrating lymphocyte (TIL) | gene.CD8 | The mean expression of CD8A and CD8B genes/the CD8 gene expression | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [17] |
Tumor-infiltrating lymphocyte (TIL) | TIS (T Cell Infiltration Score) | T cell infiltration score about nine T cell subsets | Positive | RNA-seq/MicroArray | Multiple Cancer Types | [16] |
Effector molecule | CYT (immune cytolytic activity) | Immune cytolytic activity | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [39] |
Effector molecule | IFN-gamma | IFN-γ 10-gene expression | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [15] |
Effector molecule | Expanded immune signature | IFN-γ 28-gene expression | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [15] |
Effector molecule | T cell-inflamed GEP(gene expression profiles) | IFN-γ–responsive genes expression | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [15] |
Antigen associated | CRMA (anti-CTLA-4 resistance associated MAGE-A) | MAGE-A genes expression | Negative | RNA-seq/NanoString nCounter/MicroArray | Melanoma | [40] |
Antigen presentation | APM (Antigen Presenting Machinery) | Seven antigen presenting machinery (APM) genes expression |
Positive | RNA-seq/MicroArray | Multiple Cancer Types | [16] |
Immune resistance | Pan_F_TBRS (pan-fibroblast TGF-β response signature) | Pan-fibroblast TGF-β response signature | Negative | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [10] |
Immune resistance | EMT (epithelial–mesenchymal transition) | Epithelial–mesenchymal transition (EMT)-related gene expression |
Negative | RNA-seq/NanoString nCounter/MicroArray | Melanoma, UC | [18,41] |
Immune resistance | C-ECM-up (cancer-associated extracellular matrix genes upregulated) | Cancer-associated ECM upregulated genes enrichment score | Negative | RNA-seq/MicroArray | Multiple Cancer Types | [30] |
Immune resistance | IRP (ImmuneResistanceProgram) | Resistance program that is associated with T cell exclusion and immune evasion | Negative | RNA-seq/MicroArray | Melanoma | [42] |
Immune resistance | IPRES (Innate Anti-PD-1 RESistance) | Innate anti-PD-1 resistance gene signature | Negative | RNA-seq/MicroArray | Multiple Cancer Types | [18] |
Comprehensive | TIDE (Tumor Immune Dysfunction And Exclusion) | A computational method to model two primary mechanisms of tumor immune evasion | Negative | RNA-seq/NanoString nCounter/MicroArray | Melanoma, NSCLC | [11] |
Comprehensive | IPS (Immunophenoscore) | A scoring scheme for the quantification termed immunophenoscore. | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [12] |
Comprehensive | IS (Immune Signature) | Bayesian probability of the immune signature | Positive | RNA-seq/NanoString nCounter/MicroArray | Multiple Cancer Types | [43] |